8.3% Below Target

The consensus price target for NMR is $10.2, close to the current price of $9.42 (8.3% implied move). Based on 9 analyst estimates, the stock appears fairly valued near current levels.

NMR has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $10.2 implies 8.3% upside from current levels.

With a forward P/E of 0.0716x, NMR trades at a relatively low valuation. The consensus target of $10.2 implies 8.3% appreciation, suggesting the market may be pricing in risks.

The most bullish Wall Street analyst has a price target of $10.2 for NMR, while the most conservative target is $10.2. The consensus of $10.2 represents the median expectation. Our quantitative valuation model projects a bull case target of $2355 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

NMR is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month NMR stock forecast based on 9 Wall Street analysts shows a consensus price target of $10.2, with estimates ranging from $10.2 (bear case) to $10.2 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $1787, with bear/bull scenarios of $1126/$2355.

Our quantitative valuation model calculates NMR's fair value at $1787 (base case), with a bear case of $1126 and bull case of $2355. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 43/100.

NMR trades at a forward P/E ratio of 0.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

NMR appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $10.2 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

NMR analyst price targets range from $10.2 to $10.2, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10.2 consensus represents the middle ground. Our model's $1126-$2355 range provides an independent fundamental perspective.